氩氦刀冷冻消融术治疗原发性肝癌的疗效：一项初步临床研究。
Efficacy of argon-helium cryosurgical ablation on primary hepatocellular carcinoma: a pilot clinical study.
作者信息
Zhou Lin, Yang Yong-Ping, Feng Yong-Yi, Lu Yin-Ying, Wang Chun-Ping, Wang Xin-Zhen, An Lin-Jing, Zhang Xin, Wang Fu-Sheng
机构信息
PLA Postgraduate Medical School, Beijing, PR China.
出版信息
Ai Zheng. 2009 Jan;28(1):45-8. Epub 2009 Jan 15.
BACKGROUND AND OBJECTIVE
Recent years, great progression has been made in treating primary hepatocellular carcinoma (HCC) with argon-helium cryosurgical ablation. This study was to evaluate its efficacy on unresectable primary HCC.
METHODS
A total of 124 primary HCC patients were divided into early stage, middle stage and advanced stage groups according to BCLC staging classification. Clinical symptoms, tumor size, serum level of alpha-fetoprotein (AFP), complications, and survival time were analyzed.
RESULTS
After cryoablation of the tumors, serum level of AFP was reduced in 76 (82.6%) patients, 205 (92.3%) of the 222 tumor lesions were diminished or unchanged. Untill April 2008, 14 patients survived and 110 died. The median survival time was 31.25 months in early stage group, 17.41 months in middle stage group and 6.82 months in advanced stage group.
CONCLUSION
For the patients with unresectable HCC, argon-helium cryosurgical ablation has the advantages of few complications and certain efficacy.
背景与目的
近年来，氩氦刀冷冻消融治疗原发性肝细胞癌（HCC）取得了很大进展。本研究旨在评估其对不可切除原发性肝癌的疗效。
方法
将124例原发性肝癌患者根据BCLC分期分为早期、中期和晚期组。分析临床症状、肿瘤大小、甲胎蛋白（AFP）血清水平、并发症及生存时间。
结果
肿瘤冷冻消融后，76例（82.6%）患者的AFP血清水平降低，222个肿瘤病灶中有205个（92.3%）缩小或未改变。至2008年4月，14例患者存活，110例死亡。早期组中位生存时间为31.25个月，中期组为17.41个月，晚期组为6.82个月。
结论
对于不可切除的肝癌患者，氩氦刀冷冻消融具有并发症少、疗效确切的优点。
Zotero 插件